RSV Infection

Infectious Diseases
8
Pipeline Programs
5
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
250%
Small Molecule
250%
+ 5 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
4 programs
2
2
ObeldesivirPhase 2Small Molecule1 trial
ObeldesivirPhase 2Small Molecule
GS-5806Phase 1
GS-5806Phase 11 trial
Active Trials
NCT01801293Completed8Est. Apr 2013
NCT06585150Terminated150Est. Jun 2025
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
1
MVA-mBN294BPhase 21 trial
Active Trials
NCT04752644Completed73Est. Nov 2021
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
NirsevimabPhase 2Monoclonal Antibody4 trials
Active Trials
NCT06042049Active Not Recruiting33Est. Aug 2025
NCT05437510Completed8,057Est. Apr 2025
NCT05110261Active Not Recruiting800Est. Nov 2025
+1 more trials
Sciwind Biosciences
Sciwind BiosciencesChina - Hangzhou
1 program
1
XW001Phase 1/21 trial
Active Trials
NCT05779995CompletedEst. Jan 2024
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
RSV 6120/∆NS2/1030sPhase 11 trial
NirsevimabN/AMonoclonal Antibody1 trial
Active Trials
NCT06172660RecruitingEst. Dec 2028
NCT03387137CompletedEst. May 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstraZenecaNirsevimab
AstraZenecaNirsevimab
AstraZenecaNirsevimab
Gilead SciencesObeldesivir
Bavarian NordicMVA-mBN294B
AstraZenecaNirsevimab
Sciwind BiosciencesXW001
Allergy TherapeuticsRSV 6120/∆NS2/1030s
Gilead SciencesGS-5806
Allergy TherapeuticsNirsevimab

Clinical Trials (10)

Total enrollment: 9,221 patients across 10 trials

A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab

Start: Jul 2023Est. completion: Aug 202533 patients
Phase 3Active Not Recruiting

Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

Start: Aug 2022Est. completion: Apr 20258,057 patients
Phase 3Completed

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China

Start: Nov 2021Est. completion: Nov 2025800 patients
Phase 3Active Not Recruiting

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

Start: Oct 2024Est. completion: Jun 2025150 patients
Phase 2Terminated

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

Start: Feb 2021Est. completion: Nov 202173 patients
Phase 2Completed

Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children

Start: Aug 2020Est. completion: Feb 2023100 patients
Phase 2Completed

A Study To Evaluate the Safety of XW001 Inhalation in Children With RSV

Start: Apr 2023Est. completion: Jan 2024
Phase 1/2Completed
NCT03387137Allergy TherapeuticsRSV 6120/∆NS2/1030s

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

Start: Oct 2017Est. completion: May 2021
Phase 1Completed

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

Start: Mar 2013Est. completion: Apr 20138 patients
Phase 1Completed

Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

Start: Oct 2024Est. completion: Dec 2028
N/ARecruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 9,221 patients
5 companies competing in this space